Efficacy and Safety of Honey Bee Venom ( Apis mellifera) Dermal Injections to Treat Osteoarthritis Knee Pain and Physical Disability: A Randomized Controlled Trial

• Published in: The journal of alternative and complementary medicine (New York, N.Y.) Vol. 25; no. 8; p. 845
• Main Authors: Conrad, Vicki J, Hazan, Lydie L, Latorre, Agustin J, Jakubowska, Anna, Kim, Christopher M H
• Format: Journal Article
• Language: English
• Published: United States 01.08.2019
• Subjects: Acupuncture Points; Aged; Arthralgia - physiopathology; Arthralgia - therapy; Bee Venoms - administration & dosage; Bee Venoms - adverse effects; Bee Venoms - therapeutic use; Double-Blind Method; Female; Humans; Injections, Intradermal; Knee Joint - physiopathology; Male; Middle Aged; Osteoarthritis, Knee - physiopathology; Osteoarthritis, Knee - therapy; Pain Measurement; acupuncture points; dermal injections; pain; physical function; knee osteoarthritis; bee venom
• ISSN: 1557-7708
• DOI: 10.1089/acm.2019.0121

To evaluate purified honey bee ( ) venom (HBV) biotherapy for the treatment of osteoarthritis (OA) knee pain and physical function. Five hundred and thirty-eight patients with Kellgren/Lawrence grade 1-3 radiographic knee OA and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score ≥2 were randomized 1:2 to either control ("histamine") or HBV in this double-blind study. After a dose escalation period, patients received 12 weekly dermal injections of control ("histamine") or HBV. At each of the 12 weekly visits, a set of 15 dermal injections (each containing 2.75 μg histamine or 100 μg HBV) were administered at prespecified acupuncture points (5 on each knee: knee top, eye-1 medial, eye-2 lateral, ST 34, BL 40 and 5 near the spinous processes: BL 19, 21, 23, 25, and 27). Assessments included WOMAC pain and physical function subscales, visual analog scale (VAS), patient global assessment (PGA), and physician global assessment (PhGA). Rescue medication use (acetaminophen) and routine safety parameters were monitored. HBV biotherapy demonstrated a highly significant improvement over control in WOMAC pain score after 12 weeks (1.1 U mean difference; confidence interval [95% CI]: 0.3-2.0; analysis of covariance [ANCOVA]  = 0.0010 with baseline as covariate) that was also sustained 4 weeks post-treatment. Furthermore, WOMAC physical function was significantly improved over control with HBV (3.1 U mean difference; 95% CI: 0.3-5.9; ANCOVA  = 0.0046), and sustained 4 weeks post-treatment. VAS scores were significantly improved with HBV versus control, as well as PGA and PhGA evaluations, which showed that patients responded more favorably ("very good/good") to their overall OA condition (82.0% vs. 62.4% [  = 0.0001] and 82.1% vs. 54.9% [  = 0.0015], respectively). Use of rescue acetaminophen was similar between the groups (77%-78% of patients). HBV was associated with higher incidence of injection site reactions (<5%); however, the overall safety profiles were comparable between the treatment groups. This phase 3 trial demonstrated that HBV biotherapy resulted in significant improvements in knee OA pain and physical function.